European Biosimilar Guidelines May Leave Room For Regulatory Shortcuts
Executive Summary
Marketing authorization for generic biologics may be extrapolated to additional indications approved for the reference product, according to biosimilar guidelines recently released by the European Medicines Agency
You may also be interested in...
Canada Biosimilars Proposal Requires Extra Studies To Show Substitutability
Substitution of a biosimilar for its reference brand product would not be automatic under the framework proposed by Health Canada for approving what it calls "subsequent entry biologics.
Canada Biosimilars Proposal Requires Extra Studies To Show Substitutability
Substitution of a biosimilar for its reference brand product would not be automatic under the framework proposed by Health Canada for approving what it calls "subsequent entry biologics.
EU Biosimilar Guidance Offers Window To Bypass Comparative Trials
Manufacturers seeking regulatory approval of a follow-on biologic in the EU may be able to forgo clinical comparability trials under certain conditions, according to final guidelines on similar biologics issued by the European Medicines Agency March 8